查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1511948

藥物安全檢測市場規模、佔有率和趨勢分析報告：按產品生命週期、按服務供應商、按類型、按治療領域、按工藝流程、按最終用途、按地區、細分市場預測，2024-2030 年

Pharmacovigilance Market Size, Share & Trends Analysis Report By Product Life Cycle, By Service Provider (In-house, Contract Outsourcing), By Type, By Therapeutic Area, By Process Flow, By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 295 Pages | 商品交期: 2-10個工作天內

價格

藥物安全檢測市場的成長與趨勢：

Grand View Research, Inc. 的最新報告顯示，到 2030 年，全球藥物安全檢測市場規模預計將達到 117.8 億美元。

預計2024年至2030年複合年成長率為6.8%。市場成長的主要驅動力是藥物不良反應（ADR）發生率的增加。藥品不良反應給醫療保健系統帶來了沉重負擔，並且是已開發國家發病率的明顯來源之一。根據美國國家生物技術資訊中心 (NCBI) 的數據，歐洲每年約有二十分之一的住院患者是由於 ADR 引起的。藥物安全檢測(PV) 服務在臨床試驗階段發揮重要作用，幫助製造商識別與藥物相關的不良反應。

此外，2022 年 2 月發表在《當代醫學研究與實踐雜誌》上的一篇論文，題為“接受癌症化療藥物的患者不良藥物反應的嚴重性和結果——一項前瞻性觀察研究”，根據「不良藥物不良反應的嚴重性和結果」不良 ADR 患者的結果特徵 - 一項前瞻性觀察研究表明，嚴重的ADR 每年在美國導致超過100,000 人死亡，並且在過去十年中已成為主要的健康問題。致命性心律不整和肝功能衰竭等不良反應可能導致藥物從市場上撤出，因為與其使用相關的風險超過了相關的益處。 COVID-19 大流行為光電服務供應商帶來了機會和挑戰，促進了創新平台的發展，以提高其競爭力。

例如，2020年12月，生命科學產業商業服務供應商EVERSANA與專門從事藥物開發流程自動化的生命科學軟體公司ArisGlobal合作。該合作夥伴關係旨在將端到端PV程序數位化，並在全球範圍內實現更安全、更有效的醫療保健。技術先進且方便用戶使用的軟體系統市場，如雲端基礎的光伏和藥物安全平台，預計將在預測期內支援產業成長。例如，Clinevo Technologies 提供 Clinevo Safety，這是一種雲端基礎的解決方案，涵蓋案例處理、監管提交/AS2 閘道器、PV 攝取、分析、安全訊號和其他功能。

這一一體化平台正在推動市場發展。此外，有組織的努力正在支持巴西等新興市場的成長。例如，巴西推出了一項涉及製藥業、學術界、臨床實踐和衛生當局的病患安全和 PV 計畫。該計畫由 FIPFARMA（Fundacao Instituto de Pesquisas Farmaceuticas）和藥學院（聖保羅大學）提供，並分兩批（2020 年和 2022 年）開展了 30 小時的線上課程。本課程涵蓋了重要主題，例如醫療保健和藥物安全檢測概述、藥物安全和管理以及病人安全文化。研討會解決了醫療保健專業人員 (HCP) 面臨的現實挑戰，並鼓勵協作解決問題。

視訊會議有效地吸引了醫護人員並對其進行了教育，促進了知識共用，並鼓勵了心態轉變。這項措施對參與者產生了積極影響，加強了巴西的光伏實踐。已開發國家的主要製藥公司都將重點放在外包光電服務上，以降低成本並減少營運費用。預計這將為開發中國家的 CRO（委外研發機構）創造擴大其行業佔有率的機會。製造商正在重新考慮產品開發程序，以滿足全球患者不斷成長的需求。由於這些因素，光伏服務的需求預計在預測期內將會成長。

此外，光伏產業的公司正在實施收購、合作、擴張和產品發布等策略，以擴大其產品範圍並提高市場佔有率。例如，專門從事製藥業的服務供應商Ergomed plc 於 2022 年 2 月收購了 ADAMAS Consulting Group Limited。 ADAMAS 是一家國際顧問公司，為藥品製造、臨床試驗審核和光電系統提供品質保證服務。此次收購價值 2,560 萬英鎊，預計將為 Ergomed 的收益帶來正面影響，預計未來將獲得進一步成長和戰略優勢。

藥物安全檢測市場報告亮點

  • 2023年，第四期將佔據市場主導地位，收益佔有率將超過75.85%。這是由於 ADR 事件和上市後監督的增加。
  • 由於醫藥企業旨在透過外包服務降低業務成本，2023年服務供應商產業外包市場佔有率超過60.63%。
  • 自我報告細分市場在 2023 年以超過 30.22% 的銷售佔有率引領市場。其應用包括高效且經濟高效地檢測新型、嚴重和罕見的 ADR。
  • 在生物製藥公司在慢性癌症治療方面的研究努力的推動下，2023年的治療領域中，腫瘤學佔最大佔有率，超過26.95%。
  • 預計在預測期內，案例資料管理將以流程領域中最快的複合年成長率成長 7.3%。
  • 在最終用途領域，生技公司預計將以 8.0% 的最快複合年成長率成長。這是由於我們專注於生技藥品、療法和基因療法等新產品的研究和開發。
  • 由於對開發新藥的投資、有利的法規以及強大的研究單位和臨床試驗的存在，北美在 2023 年佔據了最大的銷售佔有率，超過 32.55%。
  • 公司採用新產品發布、聯盟和收購等策略來獲得競爭優勢。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章藥物安全檢測市場變數、趨勢、範圍

  • 市場體系展望
    • 母市場分析
    • 輔助市場分析
  • 滲透率和成長前景圖
  • 藥物安全檢測市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 產業挑戰
  • 藥物安全檢測市場分析工具：Porter
  • SWOT 分析，按因素（政治/法律、經濟、技術）
  • 價值鏈分析
    • 臨床前
    • 臨床
    • PMA
  • 繪製服務交付和需求的生命週期
  • 法律規範
    • 按國家/地區分類的監管機構列表
  • 組織架構簡介
  • 定價模式
    • 按活動分類的藥品安全預算分配
    • 按發展階段分
    • 按治療區域
    • 價格水平
  • 技術時間表概述
    • 技術變革與採用
  • COVID-19 的影響
    • 近期趨勢和策略成就
    • 公司實施的策略
  • 市場趨勢
    • 資源擴展
    • 藥物安全檢測自動化
  • 通貨膨脹的影響
  • 醫學寫作與醫療安全評論的比較分析
    • 2022年醫學寫作市場展望
    • 2022 年醫療安全審查市場展望

第4章藥物安全檢測市場：依產品生命週期估算與趨勢分析

  • 2022 年及 2030 年按產品生命週期分類的市場佔有率分析
  • 產品生命週期儀表板
  • 市場定義和範圍

第5章藥物安全檢測市場：服務供應商估計與趨勢分析

  • 2023年及2030年服務供應商的市場佔有率分析
  • 服務供應商儀表板
  • 市場定義和範圍

第6章藥物安全檢測市場：按類型估計和趨勢分析

  • 2023 年和 2030 年按類型分類的市場佔有率分析
  • 類型儀表板
  • 市場定義和範圍

第7章藥物安全檢測市場：依製程流程估算與趨勢分析

  • 2023 年和 2030 年按工藝流程分類的市場佔有率分析
  • 流程儀表板
  • 市場定義和範圍

第8章藥物安全檢測市場：按治療領域估計和趨勢分析

  • 2023 年和 2030 年按治療領域分類的市場佔有率分析
  • 治療區域儀表板
  • 市場定義和範圍

第9章藥物安全檢測市場：最終用途的估計和趨勢分析

  • 2023 年和 2030 年按最終用途分類的市場佔有率分析
  • 最終使用儀表板
  • 市場定義和範圍

第10章藥物安全檢測市場：按地區、產品、服務供應商、類型和最終用途進行的估計和趨勢分析

  • 區域市場簡介
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第11章藥物安全檢測市場：競爭分析

  • 市場參與分類
  • 上市公司
  • 私人公司
  • 競爭因素和策略
  • 使用藥物安全檢測服務的醫療保健公司

第12章競爭格局

  • 公司簡介
    • ACCENTURE
    • CLINQUEST GROUP BV（LINICAL AMERICAS）
    • IQVIA Inc.
    • COGNIZANT
    • LABORATORY CORPORATION OF AMERICA HOLDINGS
    • IBM
    • ARISGLOBAL
    • ICON PLC.
    • CAPGEMINI
    • ITCLINICAL
    • TAKE SOLUTIONS LIMITED
    • PAREXEL INTERNATIONAL CORPORATION.
    • BIOCLINICA, INC.
    • WIPRO
    • UNITED BIOSOURCE LLC
    • FMD K&L（CLINCHOICE）

第13章成功策略

  • 關鍵成功/評分標準
    • 按類別
  • 選擇供應商的關鍵因素
    • 按類別
    • 按公司規模

第14章轉換成本分析

Product Code: 978-1-68038-327-0

Pharmacovigilance Market Growth & Trends:

The global pharmacovigilance market size is projected to reach USD 11.78 billion by 2030, according to a new report by Grand View Research, Inc. It is anticipated to witness growth at a CAGR of 6.8% from 2024 to 2030. The key factor responsible for the market growth is the growing incidence of Adverse Drug Reactions (ADR). ADR imposes a significant load on healthcare systems and is one of the evident grounds for morbidity in developed nations. As per the National Center for Biotechnology Information (NCBI), about 1 in 20 hospitalizations in Europe yearly are owing to ADR. Pharmacovigilance (PV) services play a vital role in the clinical trial phase by aiding manufacturers in recognizing the negative consequences associated with the drug.

Furthermore, a February 2022 article published in the Journal of Current Medicine Research and Practice titled "Characterization of Seriousness and Outcome of Adverse Drug Reactions in Patients Receiving Cancer Chemotherapy Drugs - A Prospective Observational Study" revealed that serious ADRs in the U.S. result in over 100,000 deaths annually and have been a major health concern since the past decade. ADRs, such as fatal arrhythmia and liver failure, can result in drug withdrawal from the market as the risks related to the drug usage outweigh its associated benefits. The COVID-19 pandemic presented both opportunities and challenges for PV service providers, leading to the development of innovative platforms for a competitive edge.

For instance, in December 2020, EVERSANA, a commercial services provider in the life sciences industry, collaborated with ArisGlobal, a life sciences software company specializing in automating drug development processes. This partnership was aimed to digitally transform end-to-end PV procedures, ensuring safer and more effective healthcare worldwide. The market for technologically advanced and user-friendly software systems, like cloud-based PV and drug safety platforms, is anticipated to support industry growth over the forecast period. For instance, Clinevo Technologies offers Clinevo Safety, a cloud-based solution encompassing various functionalities, such as Case Processing, Regulatory Submissions/AS2 Gateway, PV Intake, Analytics, and Safety Signals.

This all-in-one platform is driving the market forward. Furthermore, organizational initiatives support the growth of emerging markets like Brazil. For instance, a collaborative Patient Safety and PV program was introduced in Brazil, involving the pharmaceutical industry, academia, clinical practice, and health authorities. Offered by FIPFARMA (Fundacao Instituto de Pesquisas Farmaceuticas) and Pharmacy College (Universidade de Sao Paulo), the program conducted a 30-hour online course in two cohorts (2020 and 2022). It covered crucial topics, such as Healthcare and Pharmacovigilance Overview, Drug Safety & Management, and Patient Safety Culture. Workshops addressed real Challenges Healthcare Professionals (HCPs) faced and encouraged collaborative problem-solving.

Video conferences effectively engaged and educated HCPs, facilitating knowledge sharing and promoting a mindset shift. This initiative positively impacted participants and enhanced PV practices in Brazil. Key pharma companies in developed nations are concentrating on outsourcing PV services to decrease costs and reduce operational expenses. This is expected to create an opportunity for Contact Research Organizations (CROs) in developing territories to acquire more industry share. Manufacturers are renovating their product development procedures to fulfill the growing patient needs worldwide. These factors are predicted to augment the demand for PV services over the forecast period.

Furthermore, PV industry players are implementing strategies like acquisitions, collaborations, expansions, and product launches to broaden their offerings and expand their market presence. For example, in February 2022, Ergomed plc, a specialized services provider to the pharmaceutical industry, acquired ADAMAS Consulting Group Limited. ADAMAS is an international consultancy that offers quality assurance services in pharmaceutical manufacturing, clinical trial auditing, and PV systems. The acquisition, valued at £25.6 million (in pounds), is expected to favor Ergomed's earnings, with further growth and strategic advantages anticipated in the future.

Pharmacovigilance Market Report Highlights:

  • Phase IV dominated the market with a revenue share of over 75.85% in 2023. This was driven by increased ADR incidents and post-marketing surveillance
  • Contract outsourcing accounted for over 60.63% market share in the service provider segment in 2023, as pharmaceutical organizations aimed to reduce operational costs by outsourcing services
  • The spontaneous reporting type segment led the market with a revenue share of over 30.22% in 2023. Its applications include efficient and cost-effective detection of new, serious, and rare ADRs
  • Oncology held the largest share of over 26.95% in the therapeutic area segment in 2023, fueled by biopharmaceutical companies' research efforts in chronic cancer treatments
  • Case data management is anticipated to grow at the fastest CAGR of 7.3% in the process flow segment during the forecast period
  • Biotechnology companies are expected to have the fastest CAGR of 8.0% in the end-use segment. This is due to their focus on R&D for novel products, such as biologics, therapies, and gene therapies
  • North America held the largest revenue share of over 32.55% in 2023 due to investments in new drug development, favorable regulations, and a strong presence of research units and clinical trials
  • Companies are adopting strategies like new product launches, collaborations, and acquisitions to gain a competitive advantage

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Product Life Cycle
    • 1.1.2 Service Provider
    • 1.1.3 Type
    • 1.1.4 Process Flow
    • 1.1.5 Therapeutic Area
    • 1.1.6 End Use
    • 1.1.7 Regional Scope
    • 1.1.8 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database:
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research:
    • 1.3.5 Details Of Primary Research
      • 1.3.5.1 Data for primary interviews in North America
      • 1.3.5.2 Data for Primary Interviews in Europe
      • 1.3.5.3 Data for Primary Interviews in Asia Pacific
      • 1.3.5.4 Data for Primary Interviews in Latin America
      • 1.3.5.5 Data for Primary Interviews in Middle East & Africa
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Top down market estimation
      • 1.6.1.2 CAGR Calculation
      • 1.6.1.3 Key Report Updates
  • 1.7 List of Secondary Sources
  • 1.8 List of Abbreviations
  • 1.9 Market Definitions
  • 1.10 Report Objectives
    • 1.10.1 Objective 1:
    • 1.10.2 Objective 2:

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot (Product Life Cycle & Service Provider)
  • 2.3 Segment Snapshot (Type & Therapeutic Area)
  • 2.4 Segment Snapshot (Process Flow & End Use)
  • 2.5 Competitive Landscape Snapshot

Chapter 3 Pharmacovigilance Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Analysis
    • 3.1.2 Ancillary Market Analysis
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Pharmacovigilance Market Dynamics
    • 3.3.1 Market Driver Analysis
      • 3.3.1.1 Growing drug consumption and drug development rates
      • 3.3.1.2 Increasing incidence of ADR and drug toxicity
      • 3.3.1.3 Increasing trend of outsourcing pharmacovigilance services
      • 3.3.1.4 Increasing externalization of clinical trial studies by large pharmaceutical and biopharmaceutical companies
      • 3.3.1.5 Increasing regulatory Burden on Manufacturers
      • 3.3.1.6 Introduction of technologically advanced software services
      • 3.3.1.7 Constantly rising investment on R&D by healthcare companies
      • 3.3.1.8 Partnerships and collaborations between market players
    • 3.3.2 Market Restraint Analysis
      • 3.3.2.1 Shortage of skilled labor
      • 3.3.2.2 Expensive technology for small and mid-sized player
      • 3.3.2.3 Lack of recognition
      • 3.3.2.4 Scarcity of integration standards
    • 3.3.3 Industry Challenges
  • 3.4 Pharmacovigilance Market Analysis Tools: Porters
  • 3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
  • 3.6 Value Chain Analysis
    • 3.6.1 Preclinical
    • 3.6.2 Clinical
    • 3.6.3 PMA
  • 3.7 Mapping of Life Cycle against Service Offering and Their Demand
  • 3.8 Regulatory Framework
    • 3.8.1 List of Regulatory Bodies by Country
  • 3.9 Organization Structure Introduction
  • 3.10 Pricing Models
    • 3.10.1 Drug Safety Budget Allocation by Activities
    • 3.10.2 By Development Phase
    • 3.10.3 By Therapeutic Area
    • 3.10.4 Pricing Level
      • 3.10.4.1 Project management
      • 3.10.4.2 Case processing
      • 3.10.4.3 ADR Reporting
      • 3.10.4.4 Medical writing
      • 3.10.4.5 Drug safety management
  • 3.11 Technology Timeline Overview
    • 3.11.1 Changing Technology & Adoption
      • 3.11.1.1 Social Media
      • 3.11.1.2 Literature screening
      • 3.11.1.3 Automation and AI
      • 3.11.1.4 Big data analytics in PV
  • 3.12 Impact of COVID-19
    • 3.12.1 Recent Developments & Strategic Outcomes
      • 3.12.1.1 Regulatory requirements/changes due to covid-19
    • 3.12.2 Strategies Implemented by Companies
      • 3.12.2.1 IQVIA
      • 3.12.2.2 PARAXEL International Corporation
      • 3.12.2.3 Bioclinica
      • 3.12.2.4 Pharmaceutical Product Development (PPD)
      • 3.12.2.5 IBM Corporation
      • 3.12.2.6 ICON, plc
      • 3.12.2.7 PRA Health Sciences
      • 3.12.2.8 Covance Inc.
      • 3.12.2.9 ArisGlobal
      • 3.12.2.10 Linical Accelovance
      • 3.12.2.11 Laboratory Corporation of America Holdings
  • 3.13 Market Trends
    • 3.13.1 Scaling Of Resources
    • 3.13.2 Automation in Pharmacovigilance
  • 3.14 Impact of Inflation
  • 3.15 Comparative Analysis between Medical Writing vs Medical Safety Review
    • 3.15.1 Medical Writing Market Outlook, 2022
      • 3.15.1.1 Medical writing Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 3.15.2 Medical Safety Review Market Outlook, 2022
      • 3.15.2.1 Medical Safety Review market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 4 Pharmacovigilance Market: Product Life Cycle Estimates & Trend Analysis

  • 4.1 Product Life Cycle Market Share Analysis, 2022 & 2030
  • 4.2 Product Life Cycle Dashboard
  • 4.3 Market definition and scope
    • 4.3.1 Preclinical
      • 4.3.1.1 Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.2 Phase I
      • 4.3.2.1 Phase I market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.3 Phase II
      • 4.3.3.1 Phase II market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.4 Phase III
      • 4.3.4.1 Phase III market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.5 Phase IV
      • 4.3.5.1 Phase IV market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5 Pharmacovigilance Market: Service Provider Estimates & Trend Analysis

  • 5.1 Service provider Market Share Analysis, 2023 & 2030
  • 5.2 Service Provider Dashboard
  • 5.3 Market definition and scope
    • 5.3.1 IN HOUSE
      • 5.3.1.1 In house market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.3.2 Contract Outsourcing
      • 5.3.2.1 Contract outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6 Pharmacovigilance Market: Type Estimates & Trend Analysis

  • 6.1 Type Market Share Analysis, 2023 & 2030
  • 6.2 Type Dashboard
  • 6.3 Market definition and scope
    • 6.3.1 Spontaneous Reporting
      • 6.3.1.1 Spontaneous Reporting market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.2 Intensified ADR Reporting
      • 6.3.2.1 Intensified ADR Reporting market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.3 Targeted Spontaneous Reporting
      • 6.3.3.1 Targeted spontaneous reporting market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.4 Cohort Event Monitoring (CEM)
      • 6.3.4.1 CEM market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.5 EHR Mining
      • 6.3.5.1 EHR Mining market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7 Pharmacovigilance Market: Process Flow Estimates & Trend Analysis

  • 7.1 Process Flow Market Share Analysis, 2023 & 2030
  • 7.2 Process Flow Dashboard
  • 7.3 Market definition and scope
    • 7.3.1 Case Data Management
      • 7.3.1.1 Case data management market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.1.1.1 Case logging
      • 7.3.1.1.1.1 Case logging market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.1.1.2 Case data analysis
      • 7.3.1.1.2.1 Case data analysis market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.1.1.3 Medical reviewing and reporting
      • 7.3.1.1.3.1 Medical reviewing and reporting market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.2 Signal Detection
      • 7.3.2.1 Signal detection market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.2.1.1 Adverse event logging
      • 7.3.2.1.1.1 Adverse Event Logging market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.2.1.2 Adverse Event Analysis
      • 7.3.2.1.2.1 Adverse Event Analysis market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.2.1.3 Adverse Event Review & Reporting
      • 7.3.2.1.3.1 Adverse Event Review & Reporting market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.3 Risk Management System
      • 7.3.3.1 Risk Management System market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.3.1.1 Risk Evaluation System
      • 7.3.3.1.1.1 Risk Evaluation System market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.3.1.2 Risk Mitigation System
      • 7.3.2.1.2.1 Risk Mitigation System market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8 Pharmacovigilance Market: Therapeutic Area Estimates & Trend Analysis

  • 8.1 Therapeutic Area Market Share Analysis, 2023 & 2030
  • 8.2 Therapeutic Area Dashboard
  • 8.3 Market definition and scope
    • 8.3.1 Oncology
      • 8.3.1.1 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.2 Neurology
      • 8.3.2.1 Neurology market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.3 Cardiology
      • 8.3.3.1 Cardiology market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.4 Respiratory Systems
      • 8.3.4.1 Respiratory systems market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.5 Others
      • 8.3.5.1 Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9 Pharmacovigilance Market: End Use Estimates & Trend Analysis

  • 9.1 End Use Market Share Analysis, 2023 & 2030
  • 9.2 End Use Dashboard
  • 9.3 Market definition and scope
    • 9.3.1 Pharmaceuticals
      • 9.3.1.1 Pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.3.2 Biotechnology Companies
      • 9.3.2.1 Biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.3.3 Medical Device Manufacturers
      • 9.3.3.1 Medical Device Manufacturers market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.3.4 Others
      • 9.3.4.1 Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 10 Pharmacovigilance Market: Regional Estimates & Trend Analysis, By, Product, Service Providers, Type, and End Use

  • 10.1 Regional Market Snapshot
  • 10.2 North America
    • 10.2.1 North America Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.2.2 U.S.
      • 10.2.2.1 U.S. Pharmacovigilance market estimates and forecasts, 2018- 2030 (USD Million)
      • 10.2.2.2 Competitive scenario
      • 10.2.2.3 Regulatory Framework
    • 10.2.3 Canada
      • 10.2.3.1 Canada Pharmacovigilance market estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.2.3.2 Competitive scenario
      • 10.2.3.3 Regulatory Framework
  • 10.3 Europe
    • 10.3.1 Europe Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.3.2 UK
      • 10.3.2.1 UK Pharmacovigilance market estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.3.2.2 Competitive scenario
      • 10.3.2.3 Regulatory Framework
    • 10.3.3 Germany
      • 10.3.3.1 Germany Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million
      • 10.3.3.2 Competitive scenario
      • 10.3.3.3 Regulatory Framework
    • 10.3.4 France
      • 10.3.4.1 France Pharmacovigilance market estimates and forecasts, 2018- 2030 (USD Million)
      • 10.3.4.2 Competitive scenario
      • 10.3.4.3 Regulatory Framework
    • 10.3.5 Italy
      • 10.3.5.1 Italy Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
      • 10.3.5.2 Competitive scenario
      • 10.3.5.3 Regulatory Framework
    • 10.3.6 Spain
      • 10.3.6.1 Spain pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
      • 10.3.6.2 Competitive scenario
      • 10.3.6.3 Regulatory Framework
    • 10.3.7 Russia
      • 10.3.7.1 Russia Pharmacovigilance market estimates and forecasts, 2018- 2030 (USD Million)
      • 10.3.7.2 Competitive scenario
      • 10.3.7.3 Regulatory Framework
    • 10.3.8 Denmark
      • 10.3.8.1 Denmark Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.3.8.2 Competitive scenario
      • 10.3.8.3 Regulatory Framework
    • 10.3.9 Norway
      • 10.3.9.1 Norway Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.3.9.2 Competitive scenario
      • 10.3.9.3 Regulatory Framework
    • 10.3.10 Sweden
      • 10.3.10.1 Sweden Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.3.10.2 Competitive scenario
      • 10.3.10.3 Regulatory Framework
  • 10.4 Asia Pacific
    • 10.4.1 Asia Pacific Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.2 JAPAN
      • 10.4.2.1 Japan Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.4.2.2 Competitive scenario
      • 10.4.2.3 Regulatory Framework
    • 10.4.3 CHINA
      • 10.4.3.1 China Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.4.3.2 Competitive Scenario
      • 10.4.3.3 Regulatory Framework
    • 10.4.4 India
      • 10.4.4.1 India Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.4.4.2 Competitive Scenario
      • 10.4.4.3 Regulatory Framework
    • 10.4.5 Australia
      • 10.4.5.1 Australia Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.4.5.2 Competitive Scenario
      • 10.4.5.3 Regulatory Framework
    • 10.4.6 Thailand
      • 10.4.6.1 Thailand Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.4.6.2 Competitive Scenario
      • 10.4.6.3 Regulatory Framework
    • 10.4.7 South Korea
      • 10.4.7.1 South Korea Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.4.7.2 Competitive Scenario
      • 10.4.7.3 Regulatory Framework
  • 10.5 Latin America
    • 10.5.1 Latin America Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.5.2 Brazil
      • 10.5.2.1 Brazil Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.5.2.2 Competitive Scenario
      • 10.5.2.3 Regulatory Framework
    • 10.5.3 Mexico
      • 10.5.3.1 Mexico Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.5.3.2 Competitive Scenario
      • 10.5.3.3 Regulatory Framework
    • 10.5.4 Argentina
      • 10.5.4.1 Argentina Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.5.4.2 Competitive Scenario
      • 10.5.4.3 Regulatory Framework
  • 10.6 MEA
    • 10.6.1 MEA Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.6.2 South Africa
      • 10.6.2.1 South Africa Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.6.2.2 Competitive Scenario
      • 10.6.2.3 Regulatory Framework
    • 10.6.3 Saudi Arabia
      • 10.6.3.1 Saudi Arabia Pharmacovigilance Market Estimates and Forecasts, 2018- 2030 (USD Million)
      • 10.6.3.2 Competitive Scenario
      • 10.6.3.3 Regulatory Framework
    • 10.6.4 UAE
      • 10.6.4.1 UAE Arabia Pharmacovigilance Market Estimates and Forecasts, 2018- 2030 (USD Million)
      • 10.6.4.2 Competitive Scenario
      • 10.6.4.3 Regulatory Framework
    • 10.6.5 Kuwait
      • 10.6.5.1 Kuwait Pharmacovigilance Market Estimates and Forecasts, 2018- 2030 (USD Million)
      • 10.6.5.2 Competitive Scenario
      • 10.6.5.3 Regulatory Framework

Chapter 11 Pharmacovigilance Market: Competitive Analysis

  • 11.1 Market Participation Categorization
  • 11.2 Public Companies
    • 11.2.1 Company Market Position Analysis
    • 11.2.2 Company Market Share
  • 11.3 Private Companies
    • 11.3.1 List of Key Emerging Companies
  • 11.4 Competitive Factors and Strategies
    • 11.4.1 Increasing strategic collaborations and product launch
    • 11.4.2 Strategic Government initiatives which include collaborations
    • 11.4.3 Competitors increased PV awareness program
    • 11.4.4 Competitors increased collaboration and outsourcing of operations
    • 11.4.5 Consolidation Trends
  • 11.5 Healthcare Companies Using Pharmacovigilance Services
    • 11.5.1 Potential Customers
    • 11.5.2 Notable Cases
      • 11.5.2.1 Case Study 1
      • 11.5.2.1.1 Case Study 1
      • 11.5.3.1.2 Case Study 2
      • 11.5.2.2 Case Study 2
      • 11.5.2.3 Case Study 3
      • 11.5.3.4 Case Study 4
    • 11.5.3 Key Focus areas for the pharmaceutical/healthcare companies
      • 11.5.3.1 Adoption of technological advancements in life sciences industry
      • 11.5.3.2 Published survey insights - related to adoption of pharmacovigilance automation

Chapter 12 Competitive Landscape

  • 12.1 Company Profiles
    • 12.1.1 ACCENTURE
      • 12.1.1.1 Company overview
      • 12.1.1.2 Service benchmarking
      • 12.1.1.3 Financial performance
      • 12.1.1.4 Strategic initiatives
      • 12.1.1.5 SWOT Analysis
    • 12.1.2 CLINQUEST GROUP B.V. (LINICAL AMERICAS)
      • 12.1.2.1 Company overview
      • 12.1.2.2 Service benchmarking
      • 12.1.2.3 Financial performance
      • 12.1.2.4 Strategic initiatives
      • 12.1.2.5 SWOT Analysis
    • 12.1.3 IQVIA Inc.
      • 12.1.3.1 Company overview
      • 12.1.3.2 Service benchmarking
      • 12.1.3.3 Financial performance
      • 12.1.3.4 Strategic initiatives
      • 12.1.3.5 SWOT Analysis
    • 12.1.4 COGNIZANT
      • 12.1.4.1 Company overview
      • 12.1.4.2 Service benchmarking
      • 12.1.4.3 Financial performance
      • 12.1.4.4 Strategic initiatives
      • 12.1.4.5 SWOT Analysis
    • 12.1.5 LABORATORY CORPORATION OF AMERICA HOLDINGS
      • 12.1.5.1 Company overview
      • 12.1.5.2 Service benchmarking
      • 12.1.5.3 Financial performance
      • 12.1.5.4 Strategic initiatives
      • 12.1.5.5 SWOT Analysis
    • 12.1.6 IBM
      • 12.1.6.1 Company overview
      • 12.1.6.2 Service benchmarking
      • 12.1.6.3 Financial performance
      • 12.1.6.4 Strategic initiatives
      • 12.1.6.5 SWOT Analysis
    • 12.1.7 ARISGLOBAL
      • 12.1.7.1 Company Overview
      • 12.1.7.2 Service Benchmarking
      • 12.1.7.3 Financial Performance
      • 12.1.7.4 Strategic Initiatives
      • 12.1.7.5 SWOT Analysis
    • 12.1.8 ICON PLC.
      • 12.1.8.1 Company Overview
      • 12.1.8.2 Service Benchmarking
      • 12.1.8.3 Financial Performance
      • 12.1.8.4 Strategic Initiatives
      • 12.1.8.5 SWOT Analysis
    • 12.1.9 CAPGEMINI
      • 12.1.9.1 Company Overview
      • 12.1.9.2 Service Benchmarking
      • 12.1.9.3 Financial Performance
      • 12.1.9.4 Strategic Initiatives
      • 12.1.9.5 SWOT Analysis
    • 12.1.10 ITCLINICAL
      • 12.1.10.1 Company Overview
      • 12.1.10.2 Service Benchmarking
      • 12.1.10.3 Financial Performance
      • 12.1.10.4 Strategic Initiatives
      • 12.1.10.5 SWOT Analysis
    • 12.1.11 TAKE SOLUTIONS LIMITED
      • 12.1.11.1 Company Overview
      • 12.1.11.2 Service Benchmarking
      • 12.1.11.3 Financial Performance
      • 12.1.11.4 Strategic Initiatives
      • 12.1.11.5 SWOT Analysis
    • 12.1.12 PAREXEL INTERNATIONAL CORPORATION.
      • 12.1.12.1 Company Overview
      • 12.1.12.2 Service Benchmarking
      • 12.1.12.3 Financial Performance
      • 12.1.12.4 Strategic Initiatives
      • 12.1.12.5 SWOT Analysis
    • 12.1.13 BIOCLINICA, INC.
      • 12.1.13.1 Company overview
      • 12.1.13.2 Service benchmarking
      • 12.1.13.3 Financial performance
      • 12.1.13.4 Strategic initiatives
      • 12.1.13.5 SWOT Analysis
    • 12.1.14 WIPRO
      • 12.1.14.1 Company Overview
      • 12.1.14.2 Service Benchmarking
      • 12.1.14.3 Financial Performance
      • 12.1.14.4 Strategic Initiatives
      • 12.1.14.5 SWOT Analysis
    • 12.1.15 UNITED BIOSOURCE LLC
      • 12.1.15.1 Company Overview
      • 12.1.15.2 Service Benchmarking
      • 12.1.15.3 Financial Performance
      • 12.1.15.4 Strategic initiatives
      • 12.1.15.5 SWOT Analysis
    • 12.1.16 FMD K&L (CLINCHOICE)
      • 12.1.16.1 Company Overview
      • 12.1.16.2 Service Benchmarking
      • 12.1.16.3 Financial performance
      • 12.1.16.4 Strategic initiatives
      • 12.1.16.5 SWOT Analysis

Chapter 13 Winning Strategies

  • 13.1 Key Winning/Scoring Criteria
    • 13.1.1 By Categories
      • 13.1.1.1 Pharmaceuticals
      • 13.1.1.2 Biotech companies
      • 13.1.1.3 Medical device companies
  • 13.2 Key Vendor Selection Factors
    • 13.2.1 By Category
    • 13.2.2 By Company Size
      • 13.2.2.1 Key Takeaways

Chapter 14 Switching Cost Analysis

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviation
  • Table 3 Types of ADRs
  • Table 4 Adverse Drug Events (ADEs) in hospitals
  • Table 5 Pharmacovigilance outsourcing services insights
  • Table 6 List of regulations, by country
  • Table 7 Estimated Total Per-Study Costs (in $ Millions), by Phase and Therapeutic Area
  • Table 8 Case management costing by year
  • Table 9 Price by case processing volume
  • Table 10 Subscription services for medical manuscript writing
  • Table 11 Total literature searches (2013-2022)
  • Table 12 Instances of failed phase I clinical trials for COVID-19 vaccine
  • Table 13 Recruiting phase II clinical trials for oncology
  • Table 14 Outsourcing trend observed in pharmaceutical companies
  • Table 15 Recent Market Events
  • Table 16 List of Major Deals & Acquisitions
  • Table 17 List of key distributors and channel partners
  • Table 18 List of key emerging companies'/technology disruptors/innovators
  • Table 19 North America Pharmacovigilance Market, by country, 2018 - 2030 (USD Million)
  • Table 20 North America Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 21 North America Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 22 North America Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 23 U.S. Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 24 U.S. Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 25 U.S. Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 26 Canada Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 27 Canada Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 28 Canada Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 29 Europe Pharmacovigilance Market, by country, 2018 - 2030 (USD Million)
  • Table 30 Europe Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 31 Europe Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 32 Europe Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 33 Germany Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 34 Germany Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 35 Germany Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 36 UK Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 37 UK Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 38 UK Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 39 France Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 40 France Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 41 France Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 42 Italy Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 43 Italy Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 44 Italy Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 45 Spain Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 46 Spain Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 47 Sapin Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 48 Denmark Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 49 Denmark Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 50 Denmark Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 51 Sweden Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 52 Sweden Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 53 Sweden Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 54 Norway Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 55 Norway Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 56 Norway Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Pharmacovigilance Market, by country, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 61 Japan Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 62 Japan Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 63 Japan Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 64 China Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 65 China Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 66 China Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 67 India Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 68 India Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 69 India Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 70 Australia Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 71 Australia Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 72 Australia Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 73 South Korea Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 74 Thailand Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 75 Thailand Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 76 Thailand Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 77 Latin America Pharmacovigilance Market, by country, 2018 - 2030 (USD Million)
  • Table 78 Latin America Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 79 Latin America Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 80 Latin America Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 81 Brazil Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 82 Brazil Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 83 Brazil Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 84 Mexico Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 85 Mexico Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 86 Mexico Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 87 Argentina Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 88 Argentina Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 89 Argentina Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 90 MEA Pharmacovigilance Market, by country, 2018 - 2030 (USD Million)
  • Table 91 MEA Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 92 MEA Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 93 MEA Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 94 South Africa Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 95 South Africa Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 96 South Africa Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 97 Saudi Arabia Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 98 Saudi Arabia Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 99 Saudi Arabia Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 100 UAE Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 101 UAE Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 102 UAE Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 103 Kuwait Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 104 Kuwait Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 105 Kuwait Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Pharmacovigilance market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Primary interviews in North America
  • Fig. 6 Primary interviews in Europe
  • Fig. 7 Primary interviews in APAC
  • Fig. 8 Primary interviews in Latin America
  • Fig. 9 Primary interviews in MEA
  • Fig. 10 Market research approaches
  • Fig. 11 Value-chain-based sizing & forecasting
  • Fig. 12 QFD modeling for market share assessment
  • Fig. 13 Market formulation & validation
  • Fig. 14 Timeline of pharmacovigilance for a drug from development (premarket to post marketing)
  • Fig. 15 Market Snapshot
  • Fig. 16 Segment Snapshot (Product Life Cycle & Service Provider)
  • Fig. 17 Segment Snapshot (Type & Therapeutic Area)
  • Fig. 18 Segment Snapshot (Process Flow & End Use))
  • Fig. 19 Competitive Landscape Snapshot
  • Fig. 20 Penetration & growth prospect mapping
  • Fig. 21 Pharmacovigilance market dynamics
  • Fig. 22 Porter's five force model
  • Fig. 23 Pharmacovigilance - SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 24 Pharmacovigilance & Patient Safety Services - Product Life Cycle
  • Fig. 25 PV department
  • Fig. 26 PV organization structure
  • Fig. 27 Estimated budget allocation of drug safety activities at global and country-level
  • Fig. 28 Comparison between estimated global and country-level drug safety budget allocation
  • Fig. 29 Average % of drug safety budget contributed by function at a global level
  • Fig. 30 Pharmacovigilance system cost for small-sized firms and larger-sized firms
  • Fig. 31 Clinical trial cost by phase (%)
  • Fig. 32 Selected clinical trials costs based on technology
  • Fig. 33 Estimated cost of developing therapeutic medical device in the U.S.
  • Fig. 34 The average monthly cost of illness due to ADRs
  • Fig. 35 Medical Writers Employers by Industry
  • Fig. 36 Trending topics on social media (2017)
  • Fig. 37 ADR detection and from social media data
  • Fig. 38 Common literature automation tool flow
  • Fig. 39 Automation processes in PV
  • Fig. 40 Deterrents to Leveraging the Cloud (Oracle Survey)
  • Fig. 41 The three-step process to compute signal statistics from search log using big data
  • Fig. 42 Risk Management Capacity &Capability with Pharmacovigilance Using Big Data
  • Fig. 43 Pharma & Biotech R&D expense growth, 2020 (%)
  • Fig. 44 Medical writing market outlook, 2022 (USD Million)
  • Fig. 45 Medical writing market, 2018 - 2030 (USD Million)
  • Fig. 46 Global medical safety review market, 2018 - 2030 (USD Million)
  • Fig. 47 Pharmacovigilance market: Product life cycle movement analysis
  • Fig. 48 Pharmacovigilance market product life cycle dashboard
  • Fig. 49 Global Preclinical market, 2018 - 2030 (USD Million)
  • Fig. 50 Global Phase I market, 2018 - 2030 (USD Million)
  • Fig. 51 Global Phase II market, 2018 - 2030 (USD Million)
  • Fig. 52 Global Phase III market, 2018 - 2030 (USD Million)
  • Fig. 53 Adverse events reported in FAERS system, 2019 - 2022
  • Fig. 54 Global Phase IV market, 2018 - 2030 (USD Million)
  • Fig. 55 Pharmacovigilance market: Service provider movement analysis
  • Fig. 56 Pharmacovigilance Service provider dashboard
  • Fig. 57 Global In-house market, 2018 - 2030 (USD Million)
  • Fig. 58 Global contract outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 59 Pharmacovigilance market: Type movement analysis
  • Fig. 60 Pharmacovigilance type dashboard
  • Fig. 61 Global spontaneous reporting market, 2018 - 2030 (USD Million)
  • Fig. 62 Global intensified ADR reporting market, 2018 - 2030 (USD Million)
  • Fig. 63 Global targeted spontaneous reporting market, 2018 - 2030 (USD Million)
  • Fig. 64 Global CEM market, 2018 - 2030 (USD Million)
  • Fig. 65 Global EHR mining market, 2018 - 2030 (USD Million)
  • Fig. 66 Pharmacovigilance market: Process flow movement analysis
  • Fig. 67 Pharmacovigilance market process flow dashboard
  • Fig. 68 Global case data management market, 2018 - 2030 (USD Million)
  • Fig. 69 Global case logging market, 2018 - 2030 (USD Million)
  • Fig. 70 Global case data analysis market, 2018 - 2030 (USD Million)
  • Fig. 71 Global medical reviewing and reporting market, 2018 - 2030 (USD Million)
  • Fig. 72 Global signal detection market, 2018 - 2030 (USD Million)
  • Fig. 73 Global adverse event logging market, 2018 - 2030 (USD Million)
  • Fig. 74 Global adverse event analysis market, 2018 - 2030 (USD Million)
  • Fig. 75 Global adverse event review & reporting market, 2018 - 2030 (USD Million)
  • Fig. 76 Global risk management system market, 2018 - 2030 (USD Million)
  • Fig. 77 Global Risk Evaluation System market, 2018 - 2030 (USD Million)
  • Fig. 78 Global risk mitigation system market, 2018 - 2030 (USD Million)
  • Fig. 79 Pharmacovigilance market: Therapeutic area movement analysis
  • Fig. 80 Pharmacovigilance market therapeutic area dashboard
  • Fig. 81 Global oncology market, 2018 - 2030 (USD Million)
  • Fig. 82 Global neurology market, 2018 - 2030 (USD Million)
  • Fig. 83 Global cardiology market, 2018 - 2030 (USD Million)
  • Fig. 84 Global respiratory systems market, 2018 - 2030 (USD Million)
  • Fig. 85 Global others market, 2018 - 2030 (USD Million)
  • Fig. 86 Pharmacovigilance market: End use movement analysis
  • Fig. 87 Pharmacovigilance market end use dashboard
  • Fig. 88 Global pharmaceuticals market, 2018 - 2030 (USD Million)
  • Fig. 89 Global biotechnology companies' market, 2018 - 2030 (USD Million)
  • Fig. 90 Global medical device manufacturers market, 2018 - 2030 (USD Million)
  • Fig. 91 Global others market, 2018 - 2030 (USD Million)
  • Fig. 92 Regional market place: Key takeaways
  • Fig. 93 North America pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 94 U.S. key country dynamics (Part 1)
  • Fig. 95 U.S. key country dynamics (Part 2)
  • Fig. 96 U.S. pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 97 Canada key country dynamics (Part 1)
  • Fig. 98 Canada key country dynamics (Part 2)
  • Fig. 99 Canada pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 100 Europe pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 101 UK key country dynamics (Part 1)
  • Fig. 102 UK key country dynamics (Part 2)
  • Fig. 103 UK pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 104 Germany key country dynamics (Part 1)
  • Fig. 105 Germany key country dynamics (Part 2)
  • Fig. 106 Germany pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 107 France key country dynamics (Part 1)
  • Fig. 108 France key country dynamics (Part 2)
  • Fig. 109 France pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 110 Italy key country dynamics (Part 1)
  • Fig. 111 Italy key country dynamics (Part 2)
  • Fig. 112 Italy pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 113 Spain key country dynamics (Part 1)
  • Fig. 114 Spain key country dynamics (Part 2)
  • Fig. 115 Spain pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 116 Russia key country dynamics
  • Fig. 117 Russia pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 118 Denmark key country dynamics (Part 1)
  • Fig. 119 Denmark key country dynamics (Part 2)
  • Fig. 120 Denmark pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 121 Norway key country dynamics (Part 1)
  • Fig. 122 Norway key country dynamics (Part 2)
  • Fig. 123 Norway pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 124 Sweden key country dynamics (Part 1)
  • Fig. 125 Sweden key country dynamics (Part 2)
  • Fig. 126 Sweden pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 127 Asia Pacific Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 128 Japan pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 129 China key country dynamics (Part 1)
  • Fig. 130 China key country dynamics (Part 2)
  • Fig. 131 China pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 132 India key country dynamics (Part 1)
  • Fig. 133 India key country dynamics (Part 2)
  • Fig. 134 India pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 135 Australia pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 136 Thailand key country dynamics (Part 1)
  • Fig. 137 Thailand key country dynamics (Part 2)
  • Fig. 138 Thailand pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 139 South Korea pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 140 Latin America pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 141 Brazil pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 142 Mexico key country dynamics
  • Fig. 143 Mexico pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 144 Argentina pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 145 MEA pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 146 South Africa pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 147 Saudi Arabia pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 148 UAE key country dynamics (Part 1)
  • Fig. 149 UAE key country dynamics (Part 2)
  • Fig. 150 UAE pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 151 Kuwait pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 152 Market participant categorization
  • Fig. 153 Company market position analysis
  • Fig. 154 Estimated company market share analysis, 2022 (%)
  • Fig. 155 SWOT - Accenture
  • Fig. 156 SWOT - Linical Americas
  • Fig. 157 SWOT - IQVIA
  • Fig. 158 SWOT - Cognizant
  • Fig. 159 SWOT - Laboratory Corporation of America Holdings
  • Fig. 160 SWOT - IBM Corporation
  • Fig. 161 SWOT - ArisGlobal
  • Fig. 162 SWOT - ICON plc
  • Fig. 163 SWOT - Capgemini
  • Fig. 164 SWOT - ITClinical
  • Fig. 165 SWOT - Take Solutions
  • Fig. 166 SWOT - Parexel International Corporation
  • Fig. 167 SWOT - Clario
  • Fig. 168 SWOT - Wipro
  • Fig. 169 SWOT - United BioSource LLC
  • Fig. 170 SWOT - FMD K&L
  • Fig. 171 Commonly outsourced PV activities
  • Fig. 172 Vendor selection criteria